- Home
- CMPS vs SABA Comparison
CMPS vs SABA Comparison
Compare CMPS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- SABA
- Stock Information
- Founded
- CMPS 2020
- SABA 1988
- Country
- CMPS United Kingdom
- SABA United States
- Employees
- CMPS N/A
- SABA N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- CMPS Health Care
- SABA
- Exchange
- CMPS Nasdaq
- SABA Nasdaq
- Market Cap
- CMPS 246.5M
- SABA 233.0M
- IPO Year
- CMPS 2020
- SABA N/A
- Fundamental
- Price
- CMPS $3.51
- SABA $8.34
- Analyst Decision
- CMPS Strong Buy
- SABA
- Analyst Count
- CMPS 6
- SABA 0
- Target Price
- CMPS $20.20
- SABA N/A
- AVG Volume (30 Days)
- CMPS 836.8K
- SABA 290.0K
- Earning Date
- CMPS 05-07-2025
- SABA 01-01-0001
- Dividend Yield
- CMPS N/A
- SABA 12.91%
- EPS Growth
- CMPS N/A
- SABA N/A
- EPS
- CMPS N/A
- SABA N/A
- Revenue
- CMPS N/A
- SABA N/A
- Revenue This Year
- CMPS N/A
- SABA N/A
- Revenue Next Year
- CMPS N/A
- SABA N/A
- P/E Ratio
- CMPS N/A
- SABA N/A
- Revenue Growth
- CMPS N/A
- SABA N/A
- 52 Week Low
- CMPS $2.49
- SABA $3.64
- 52 Week High
- CMPS $9.63
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- CMPS 60.07
- SABA 42.34
- Support Level
- CMPS $2.94
- SABA $8.00
- Resistance Level
- CMPS $3.11
- SABA $8.40
- Average True Range (ATR)
- CMPS 0.22
- SABA 0.27
- MACD
- CMPS 0.11
- SABA 0.01
- Stochastic Oscillator
- CMPS 93.57
- SABA 42.65
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.